Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer

被引:346
作者
Lin, Nancy U. [1 ]
Carey, Lisa A. [1 ]
Liu, Minetta C. [1 ]
Younger, Jerry [1 ]
Come, Steven E. [1 ]
Ewend, Matthew [1 ]
Harris, Gordon J. [1 ]
Bullitt, Elizabeth [1 ]
Van den Abbeele, Annick D. [1 ]
Henson, John W. [1 ]
Li, Xiaochun [1 ]
Gelman, Rebecca [1 ]
Burstein, Harold J. [1 ]
Kasparian, Elizabeth [1 ]
Kirsch, David G. [1 ]
Crawford, Ann [1 ]
Hochberg, Fred [1 ]
Winer, Eric P. [1 ]
机构
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
关键词
D O I
10.1200/JCO.2007.12.3588
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose One third of women with advanced human epidermal growth factor receptor 2 (HER-2)-positive breast cancer develop brain metastases; a subset progress in the CNS despite standard approaches. Medical therapies for refractory brain metastases are neither well-studied nor established. We evaluated the safety and efficacy of lapatinib, an oral inhibitor of epidermal growth factor receptor (EGFR) and HER-2, in patients with HER-2-positive brain metastases. Patients and Methods Patients had HER-2-positive breast cancer, progressive brain metastases, prior trastuzumab treatment, and at least one measurable metastatic brain lesion. Patients received lapatinib 750 mg orally twice a day. Tumor response was assessed by magnetic resonance imaging every 8 weeks. The primary end point was objective response (complete response [CR] plus partial response [PR]) in the CNS by Response Evaluation Criteria in Solid Tumors (RECIST). Secondary end points included objective response in non-CNS sites, time to progression, overall survival, and toxicity. Results Thirty-nine patients were enrolled. All patients had developed brain metastases while receiving trastuzumab; 37 had progressed after prior radiation. One patient achieved a PR in the brain by RECIST (objective response rate 2.6%, 95% conditional CI, 0.21% to 26%). Seven patients (18%) were progression free in both CNS and non-CNS sites at 16 weeks. Exploratory analyses identified additional patients with some degree of volumetric reduction in brain tumor burden. The most common adverse events (AEs) were diarrhea (grade 3, 21%) and fatigue (grade 3, 15%). Conclusion The study did not meet the predefined criteria for antitumor activity in highly refractory patients with HER-2-positive brain metastases. Because of the volumetric changes observed in our exploratory analysis, further studies are underway utilizing volumetric changes as a primary end point.
引用
收藏
页码:1993 / 1999
页数:7
相关论文
共 36 条
[1]   CONFIDENCE-LIMITS FOR PROBABILITY OF RESPONSE IN MULTISTAGE PHASE-II CLINICAL-TRIALS [J].
ATKINSON, EN ;
BROWN, BW .
BIOMETRICS, 1985, 41 (03) :741-744
[2]   Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma [J].
Bendell, JC ;
Domchek, SM ;
Burstein, HJ ;
Harris, L ;
Younger, J ;
Kuter, I ;
Bunnell, C ;
Rue, M ;
Gelman, R ;
Winer, E .
CANCER, 2003, 97 (12) :2972-2977
[3]  
Blackwell KL, 2005, J CLIN ONCOL, V23, p193S
[4]  
Blackwell KL, 2004, J CLIN ONCOL, V22, p196S
[5]  
BOOGERD W, 1992, CANCER, V69, P972, DOI 10.1002/1097-0142(19920215)69:4<972::AID-CNCR2820690423>3.0.CO
[6]  
2-P
[7]  
Burris HA, 2003, P AN M AM SOC CLIN, V22, P248
[8]   Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: Multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm [J].
Burstein, HJ ;
Harris, LN ;
Marcom, PK ;
Lambert-Falls, R ;
Havlin, K ;
Overmoyer, B ;
Friedlander, RJ ;
Gargiulo, J ;
Strenger, R ;
Vogel, CL ;
Ryan, PD ;
Ellis, MJ ;
Nunes, RA ;
Bunnell, CA ;
Campos, SM ;
Hallor, M ;
Gelman, R ;
Winer, EP .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (15) :2889-2895
[9]  
BURSTEIN HJ, 2004, 29 ANN C EUR SOC MED
[10]   Gefitinib in patients with brain metastases from non-small-cell lung cancer:: a prospective trial [J].
Ceresoli, GL ;
Cappuzzo, F ;
Gregorc, V ;
Bartolini, S ;
Crinó, L ;
Villa, E .
ANNALS OF ONCOLOGY, 2004, 15 (07) :1042-1047